Answers are grounded in this paper and cite their sources.
Etentamig is an investigational B-cell maturation antigen (BCMA) x CD3 bispecific T-cell engager, composed of a low-affinity CD3 binding domain, potentially reducing cytokine release syndrome (CRS) and infections, a high-avidity bivalent BCMA-binding domain, and retained FcRn binding supporting monthly (Q4W) dosing after a single step-up dose (SUD). We report long-term efficacy and safety from the ongoing, open-label, phase 1 (dose escalation/expansion; NCT03933735) and Arm A of the phase 1b (NCT05650632) studies of etentamig in adult patients with relapsed/refractory multiple myeloma, triple-class exposure, and ≥3 prior lines of therapy (LoT). In phase 1, patients received etentamig 60 mg Q4W or 40 mg Q3W, and in phase 1b, a SUD on Day 1 and 60 mg Q4W on Day 4. Among 146 patients (median age: 68 years; median [range] prior LoT: 4 [3-23]), median follow-up was 13 months (range: 1-48). Objective responses and ≥ very good partial responses occurred in 66% and 54% of patients. Median duration of response and progression-free survival were not reached. Pooled data suggest etentamig has a manageable safety profile, with Grade 3/4 neutropenia and infection occurring in 38% and 23% of patients. In phase 1b Arm A (n=23), overall CRS incidence was 30% (26% Grade 1; 4% Grade 2) with modified dexamethasone premedication and 1 SUD; median onset was 22.3 hours (range: 5.5-29.6) hours, with resolution in 20.7 hours (range: 1.8-131.7). Etentamig's molecular design may be associated with the observed clinical efficacy and tolerability while also potentially supporting extended dosing intervals.
No takes yet. Share an insight, caveat, or question.
Baljević et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: